Article info

Download PDFPDF
THU0149 The 54-Week Results of Interferon-γ Release Assay in A Phase III Study Comparing SB2, An Infliximab Biosimilar, To Infliximab Reference Product in Patients with Rheumatoid Arthritis

Authors

Citation

Durez P, Mysler E, Smolen J, et al
THU0149 The 54-Week Results of Interferon-γ Release Assay in A Phase III Study Comparing SB2, An Infliximab Biosimilar, To Infliximab Reference Product in Patients with Rheumatoid Arthritis

Publication history

  • First published July 15, 2016.
Online issue publication 
February 10, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.